

## Curis to Present at the 13th Annual Needham Healthcare Conference

LEXINGTON, Mass., April 2, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the 13<sup>th</sup> Annual Needham Healthcare Conference at 1:40 p.m. ET on April 9, 2014, in New York City.

Dan Passeri, Chief Executive Officer, will provide an overview of Curis' proprietary cancer programs including its dual histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) inhibitor, CUDC-907, and its antagonist of inhibitor of apoptosis (IAP) proteins, CUDC-427. Mr. Passeri will also provide an overview of Curis' partnered programs including Erivedge® (vismodegib), a hedgehog pathway inhibitor developed under collaboration with Genentech/Roche that is the only approved medicine for patients with advanced basal cell carcinoma, and HSP90 inhibitor, Debio 0932, that is in clinical development by Curis' collaborator Debiopharm.

A corresponding webcast of the presentation can be accessed by visiting:

<http://wsw.com/webcast/needham65/cris/>

The audio webcast will be archived shortly after the live event and available for 30 days following the conference. In addition, it will be available for 30 days on the Investor Relations section of the Curis website at [www.curis.com](http://www.curis.com).

### About Curis, Inc.

Curis is an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers. Curis is seeking to further the development of its pipeline of proprietary targeted cancer drug candidates, including CUDC-907, a dual HDAC and PI3K inhibitor, and CUDC-427, a small molecule antagonist of IAP proteins. Curis is also engaged in a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge®, the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma. Curis-discovered HSP90 inhibitor, Debio 0932 is being studied in patients with advanced lung and kidney cancers by partner Debiopharm. For more information, visit Curis' website at [www.curis.com](http://www.curis.com)

CONTACT: For More Information:

Mani Mohindru, Ph.D.

Vice President, Corporate Strategy and Investor Relations

Curis, Inc.

617-503-6605

[mmohindru@curis.com](mailto:mmohindru@curis.com)

Michael P. Gray

Chief Financial Officer

Curis, Inc.

617-503-6632

[mgray@curis.com](mailto:mgray@curis.com)

---

<https://investors.curis.com/Curis-to-Present-at-the-13th-Annual-Needham-Healthcare-Conference>